Table 2

Univariable and multivariable Cox regression analysis (n=114)

OSUnivariableMultivariableMultivariable +interaction
P valueHR95% CIP valueHR95% CIP valueHR95% CI
LowerUpperLowerUpperLowerUpper
HLA-I zygosity (hetero vs homo) 0.020 2.17 1.13 4.17 0.023 2.19 1.12 4.30 0.004 3.70 1.53 8.95
Age (<65 vs ≥65)0.5340.830.451.510.2290.670.341.290.4000.750.381.47
Sex (M vs F)0.5981.140.701.880.0941.700.913.160.2541.440.772.71
PDL1 (≥50% vs <50%)0.9160.970.531.770.4980.810.431.500.7551.120.542.35
ECOG (≤1 vs ≥2)0.2161.630.723.510.1411.810.823.970.1131.890.864.17
NLR (≤5 vs >5)0.0591.780.983.24 0.002 2.95 1.51 5.75 0.001 2.97 1.53 5.76
Therapy type (αPD1 vs αPDL1) <0.001 3.16 1.66 5.99 <0.001 4.36 2.18 8.75 <0.001 4.26 2.12 8.59
HLA-I*PDL10.0940.260.051.26
PFS
HLA-I zygosity (hetero vs homo)0.0931.620.922.860.0591.770.983.20 0.043 2.18 1.02 4.66
Age (<65 vs ≥65)0.3520.790.481.300.2620.740.431.260.3690.780.451.34
Sex (M vs F)0.7801.060.711.590.1111.510.912.490.1761.430.852.38
PDL1 (≥50% vs <50%)0.3471.260.782.060.7211.100.661.820.4701.240.692.23
ECOG (≤1 vs ≥2)0.4261.320.672.580.4011.350.672.730.3951.360.672.75
NLR (≤5 vs >5)0.6261.130.671.860.1131.560.902.700.1191.540.892.67
Therapy type (αPD1 vs αPDL1) <0.001 2.93 1.75 4.88 <0.001 3.18 1.84 5.47 <0.001 3.07 1.77 5.32
HLA-I*PDL10.4040.580.162.10
  • ECOG, Eastern Cooperative Oncology Group; F, female; HLA, human leukocyte antigen; M, male; NLR, neutrophil/lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PD1/PDL1, programmed cell death protein-1/programmed death ligand 1; PFS, progression free survival.